Sanofi unwilling to increase bid with Genzyme
NEW YORK Biotech drug maker Genzyme’s takeover by French drug maker Sanofi-Aventis may have run into trouble, according to published reports.
Bloomberg reported Wednesday that Sanofi was unwilling to raise its offer of $70 per share for Genzyme, a Cambridge, Mass.-based company that has carved a niche for itself by manufacturing treatments for such rare genetic disorders as Fabry disease and Pompe disease but lately has been dogged by manufacturing problems.
Sanofi’s current offer stands at $69 a share, a total of around $17.6 billion, according to Bloomberg.
Georgia-Pacific Professional launches Spread Wellness campaign
ATLANTA As the cold and flu season approaches, a paper company is launching a campaign to combat bad habits that contribute to the illnesses’ spread.
Georgia-Pacific Professional announced Wednesday the launch of its Spread Wellness campaign, designed to teach people proper techniques of washing and drying hands when away from home, especially after coughing and sneezing; according to a 2009 study by the Soap and Detergent Association, 39% of people seldom do so.
“With the easy transfer of germs and diseases, we all need to be more aware of our surroundings,” Georgia-Pacific Professional president Bill Sleeper stated. “We need to practice good hygiene habits ourselves and share these tips with those we interact with.”
Medicare bid to simplify Part D program could shift many seniors, study predicts
WASHINGTON More than 3 million older Americans may have to switch to a different Medicare drug plan next year, a new study from health research and consulting firm Avalere Health revealed.
The study results, reported by the Associated Press, point to a potential snag in the Obama Administration’s plans for a smooth transition to a reformed healthcare system. According to Avalere and the AP, prescription drug plans serving more than 3 million Medicare Part D beneficiaries may be eliminated in 2011 after the Centers for Medicare and Medicaid Services completes a plan to cull redundant, higher-cost or less-efficient Part D plans from the federal drug benefit program for seniors.
That could force those seniors to choose a new plan, the AP reported, despite assurances from the White House during the long campaign to pass health-reform legislation that Americans could keep their current health plans if they chose to.
Avalere cited one instance where the change already is occurring. Medicare officials, according to the AP, already have notified such major prescription benefit management plans as CVS Caremark and the AARP that they must pare the number of drug plan options they offer Part D members. The goal is to simplify the dizzying array of choices available to Medicare beneficiaries in many regions of the country.
On the plus side, administration officials said, the change doesn’t mean seniors will lose coverage. And the elimination of redundant Part D drug plans — which number some 1,600 in total, according to the AP — also will reduce confusion among Medicare recipients and make it easier for newly eligible members to choose among a smaller array of coverage, cost and drug-formulary options.
Medicare also is trying to smooth the way to a more seamless transition for seniors who will be affected by the elimination of some plans, the AP reported, in part by automatically reassigning some beneficiaries to a similar plan offered by their insurer. The agency reportedly will unveil its approved list of Part D drug plans in late September, and the result, the AP indicated could be as much as a 25% reduction in the number of plans.